Home > Insider Trading > Filing (0001127602-12-023278)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
318154	Amgen Inc	AMGN	Biological Products, (No Disgnostic Substances) (2836)	953540776

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1541946	E Sean Harper	One Amgen Center Drive Thousand Oaks CA 91320-1799	Evp, Research & Development	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2012-07-27	1,391	$71.88	53,823	No	4	M	Direct
Common Stock	Acquisiton	2012-07-27	8,000	$58.43	61,823	No	4	M	Direct
Common Stock	Acquisiton	2012-07-27	16,109	$71.88	69,932	No	4	M	Direct
Common Stock	Acquisiton	2012-07-27	14,400	$69.78	84,332	No	4	M	Direct
Common Stock	Disposition	2012-07-27	39,900	$82.33	52,432	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Iso (Right to Buy)	Disposition	2012-07-27	1,391	$0.00	1,391	$71.88
Common Stock	Nqso (Right to Buy)	Disposition	2012-07-27	8,000	$0.00	8,000	$58.43
Common Stock	Nqso (Right to Buy)	Disposition	2012-07-27	16,109	$0.00	16,109	$71.88
Common Stock	Nqso (Right to Buy)	Disposition	2012-07-27	14,400	$0.00	14,400	$69.78

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2010-04-03	2013-04-03	No	4	M	Direct
16,000	2012-04-26	2020-04-26	No	4	M	Direct
0	2007-04-03	2013-04-03	No	4	M	Direct
0	2008-02-08	2014-02-08	No	4	M	Direct

Footnotes

The price reported is an average price. The prices ranged from $82.28 to $82.48 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,125 RSUs which fully vest on 4/28/2013; 2,300 RSUs which vest in two equal annual installments of 1,150 each commencing 4/26/2013; 25,000 RSUs which fully vest on 12/31/2014; 6,000 RSUs which vest in two equal installments of 1,980 each on 4/25/2013 and 4/25/2014 and one installment of 2,040 on 4/25/2015; and 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.